REGISTERED NUMBER: |
FINANCIAL STATEMENTS |
FOR THE PERIOD |
6 DECEMBER 2023 TO 31 DECEMBER 2024 |
FOR |
MARENGO THERAPEUTICS LIMITED |
REGISTERED NUMBER: |
FINANCIAL STATEMENTS |
FOR THE PERIOD |
6 DECEMBER 2023 TO 31 DECEMBER 2024 |
FOR |
MARENGO THERAPEUTICS LIMITED |
MARENGO THERAPEUTICS LIMITED (REGISTERED NUMBER: 15331206) |
CONTENTS OF THE FINANCIAL STATEMENTS |
for the Period 6 DECEMBER 2023 TO 31 DECEMBER 2024 |
Page |
Company Information | 1 |
Balance Sheet | 2 |
Notes to the Financial Statements | 3 |
MARENGO THERAPEUTICS LIMITED |
COMPANY INFORMATION |
for the Period 6 DECEMBER 2023 TO 31 DECEMBER 2024 |
DIRECTORS: |
REGISTERED OFFICE: |
REGISTERED NUMBER: |
SENIOR STATUTORY AUDITOR: |
AUDITORS: |
Accountants and Statutory Auditors |
Five Ways |
57-59 Hatfield Road |
Potters Bar |
Hertfordshire |
EN6 1HS |
MARENGO THERAPEUTICS LIMITED (REGISTERED NUMBER: 15331206) |
BALANCE SHEET |
31 DECEMBER 2024 |
Notes | £ |
CURRENT ASSETS |
Debtors | 5 |
Cash at bank |
CREDITORS |
Amounts falling due within one year | 6 |
NET CURRENT LIABILITIES | ( |
) |
TOTAL ASSETS LESS CURRENT LIABILITIES |
( |
) |
CAPITAL AND RESERVES |
Called up share capital |
Retained earnings | ( |
) |
( |
) |
The financial statements were approved by the Board of Directors and authorised for issue on |
MARENGO THERAPEUTICS LIMITED (REGISTERED NUMBER: 15331206) |
NOTES TO THE FINANCIAL STATEMENTS |
for the Period 6 DECEMBER 2023 TO 31 DECEMBER 2024 |
1. | STATUTORY INFORMATION |
Marengo Therapeutics Limited is a |
The presentation currency of the financial statements is the Pound Sterling (£). |
2. | ACCOUNTING POLICIES |
Basis of preparing the financial statements |
Going Concern |
Notwithstanding the net liabilities on the balance sheet of £149,574, the Directors of Marengo Therapeutics Limited are satisfied that the accounts should be prepared on a going concern basis. They have received assurances from Marengo Therapeutics, Inc. (the ultimate parent company of Marengo Therapeutics Limited), that there are sufficient funds in place for at least 12 months from the signing of the accounts and that they will continue to support Marengo Therapeutics Limited for at least 12 months from the date of approval of these financial statements to enable the company to continue to trade. |
Turnover |
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. |
Taxation |
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
Current or deferred taxation assets and liabilities are not discounted. |
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
Deferred tax |
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference. |
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
MARENGO THERAPEUTICS LIMITED (REGISTERED NUMBER: 15331206) |
NOTES TO THE FINANCIAL STATEMENTS - continued |
for the Period 6 DECEMBER 2023 TO 31 DECEMBER 2024 |
2. | ACCOUNTING POLICIES - continued |
Foreign currencies |
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result. |
3. | EMPLOYEES AND DIRECTORS |
The average number of employees during the period was |
4. | AUDITORS' REMUNERATION |
£ |
Fees payable to the company's auditors for the audit of the company's financial statements |
17,400 |
5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
£ |
Other debtors |
6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
£ |
Taxation and social security |
Other creditors |
7. | DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006 |
The Report of the Auditors was unqualified. |
for and on behalf of |
8. | RELATED PARTY DISCLOSURES |
During the year, the company received £405,978 in management charges from Marengo Therapeutics Inc., the ultimate controlling party. |
9. | ULTIMATE CONTROLLING PARTY |
The ultimate controlling party is Marengo Therapeutics, Inc. by virtue of its shareholding. |